Windlas Biotech Ratios

Windlas Biotech Ltd Ratios

The Windlas Biotech Ltd Ratios page provides a complete fundamental analysis of Windlas Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Windlas Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Windlas Biotech Ltd (NSE: WINDLAS, BSE: 543329) is currently trading at ₹755, with a market capitalization of ₹15.98B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Windlas Biotech Ltd remains a key stock for fundamental analysis using Windlas Biotech Ltd Ratios.

Windlas Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Windlas Biotech Ltd P/E ratio currently stands at 36.07, making it one of the most tracked metrics in Windlas Biotech Ltd Ratios.

Historically, the Windlas Biotech Ltd P/E ratio has shown strong fluctuations:

• 2024: 36.07
• 2023: 18.38
• 2022: 11.43
• 2021: 11.31
• 2020: 0

The rising Windlas Biotech Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Windlas Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.31.

Historical P/B trend:

• 2024: 4.31
• 2023: 2.37
• 2022: 1.17
• 2021: 1.16

Windlas Biotech Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Windlas Biotech Ltd P/S ratio currently stands at 2.90, an important part of Windlas Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.90
• 2023: 1.70
• 2022: 0.95
• 2021: 0.93

The rising Windlas Biotech Ltd P/S ratio indicates improved revenue valuation by investors.

Windlas Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Windlas Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 33.62.

Historical Windlas Biotech Ltd Price to Cash Flow Ratio:

• 2024: 33.62
• 2023: 9.76
• 2022: 7.53
• 2021: 41.90
• 2020: 0

The rising Windlas Biotech Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Windlas Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Windlas Biotech Ltd EV currently stands at ₹19.93B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 19.93B
• 2023: 8.69B
• 2022: 3.6B
• 2021: 2.59B

Windlas Biotech Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Windlas Biotech Ltd EV/EBITDA ratio is currently 21.05, a key metric in Windlas Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 21.05
• 2023: 11.04
• 2022: 5.95
• 2021: 4.98

Higher Windlas Biotech Ltd EV/EBITDA suggests premium valuation.

Windlas Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Windlas Biotech Ltd D/E ratio is currently 0.06, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.06
• 2023: 0.01
• 2022: 0.01
• 2021: 0.02

Windlas Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Windlas Biotech Ltd ROE currently stands at 12.76%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 12.76
• 2023: 13.66
• 2022: 10.70
• 2021: 12.83

Windlas Biotech Ltd maintains stable profitability levels.

Windlas Biotech Ltd Ratios Analysis Summary

The Windlas Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Windlas Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Windlas Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.